Belite Bio is a San Diego drug developer working on oral treatments for degenerative retinal diseases that cause vision loss. BLTE reports earnings on Mon, Nov 9, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 5 firms (5 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Sep 9 | Mizuho | Target raised | Buy | |
| Sep 8 | HC Wainwright & Co. | Target raised | Buy | |
| Sep 4 | Canaccord Genuity | Initiated | Buy | |
| Aug 14 | Morgan Stanley | Maintained | Buy | |
| Aug 14 | Cantor Fitzgerald | Maintained | Buy |
Whale Options Flow
90DNo whale options trades in BLTE in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether BLTE is in one of them and how their past BLTE trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered BLTE in an article yet. Here's the latest on the wider market.
About Belite Bio
Belite Bio is a drug development company based in San Diego, California. It is developing tinlarebant, a tablet taken once a day, for people with degenerative retinal diseases that cause progressive vision loss, including geographic atrophy and Stargardt disease type 1. The company also has an earlier stage oral compound aimed at metabolic conditions such as fatty liver disease and type 2 diabetes. Its intended users are patients with these eye conditions and the doctors who would treat them if a product is approved.
- Headquarters
- San Diego, CA